The varinolic cannabinoids are considered rare but are now emerging as new targets of selective breeding. None of the varins are scheduled as a controlled substance. Nor are they analogues of any such substances.
CBVD isolate is a crystallized powder. THCV isolate is a solid at room temperature and highly subject to oxidative discoloration. The purity of these varins (>98% pure) have been tested by HPLC, GCMS, LC-MS, NMR, IR, melting point, and elemental analysis. All analytical test results demonstrated the high quality and purity of PPM’s varin isolates.
Two of the varins – CBDV and THCV – have shown to have medicinal and wellness properties. Varins contain two fewer carbon atoms than their non-varin counterparts (CBD and THC) making these cannabinoids fundamentally different on a molecular level and therefore have different physiological effects due to different binding in the endocannabinoid system.
Tetrahydrocannabivarin (THCV)— THCV can decrease signs of inflammation and inflammatory pain, a combination that could be useful in topical analgesics. (Hyperlink 6) THCV also has been found to suppress basal sebaceous lipid synthesis, which could help acne sufferers whose condition is triggered by excessive oil production. Experimental Dermatology noted that of all of the phytocannabinoids examined, THCV showed the most promise of becoming a “highly efficient, novel anti-acne agent.” (Hyperlink 1) THCV is also a new potential cannabinoid to treat obesity, diabetes, and promote weight loss by indirect binding to the CB1 receptor of the endocannabinoid system. (Hyperlink 7)
Continuous research and reliable data will demonstrate the need for these rare cannabinoids providing opportunities for brands in the plant-based health and wellness sector.
Cannabidivarin (CBDV)—Recent studies indicate CBDV may help dry skin syndrome as well as acne. (Hyperlink 1) Researchers also found that CBDV may reduce allergic inflammation, atopic dermatitis, acne and seborrhea (a.k.a. dandruff). (Hyperlink 2) These properties could make CBDV ideal for incorporating into hypoallergenic products, or topicals designed for sensitive, itch-prone skin. Anticonvulsant properties of CBDV/ CBD were reported by suppressing an epilepsy gene providing evidence of the entourage effect as well as the importance of unique ratios and formulations. (Hyperlink 3 and 4) This research strongly supports the potential of CBDV as a potential treatment of epilepsy. In fact, GW Pharmaceuticals is conducting a human trial to treat epilepsy with CBDV. (Hyperlink 5)
- Hyperlink 1: https://pubmed.ncbi.nlm.nih.gov/27094344
- Hyperlink 2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429381/
- Hyperlink 3: https://pubmed.ncbi.nlm.nih.gov/23902406
- Hyperlink 4: https://pubmed.ncbi.nlm.nih.gov/24282673
- Hyperlink 5: http://www.globenewswire.com/news-release/2014/03/17/618576/10072767/en/GW-Pharmaceuticals-Provides-Update-on-Cannabinoid-Pipeline.html
- Hyperlink 6: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931567/
- Hyperlink 7: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671751/
All studies reported here have been published in the scientific peer-reviewed literature. From our survey and in our judgement, the articles cited are recent and relevant to the potential health and wellness benefits of rare cannabinoids but does not include all literature that exists. It must be noted that most clinical trials have been performed on the animal model or in vitro on cells. More research is required including human trials to demonstrate and understand efficacy, serving and dosing sizes, potential side effects, effects on at-risk populations, and drug interactions related to the use of minor cannabinoids.